Purified Rabies Vaccine for Human Use (Chick-embryo Cell)

Evaluate the Immunogenicity and Safety of Rabies Vaccine Given in a Post-exposure Prophylaxis Regimen to Healthy Children and Adults Aged 10-60 Years.

Evaluate the immunogenicity and safety of rabies vaccine given in a post-exposure prophylaxis regimen to healthy children and adults aged 10-60 years.

Inclusion Criteria:

• male and female healthy subjects aged 10-60 years old

Exclusion Criteria:

• history of rabies immunization
• previous exposure to a suspect rabid animal within the last 12 months
• any significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the past 7 days
• treatment with corticosteroids, immunosuppressive or anti-malaria drugs during the two month period before enrollment
• known/suspected immunodeficiency, or autoimmune disease, or any immunologic disorder
• known hypersensitivity to neomycin, tetracycline, amphotericin-B, or any other vaccine component